Background
==========

*Yersinia pestis*(*Yp*) is one of the most virulent known bacteria \[[@B1]\] and a potential agent of bioterrorism and biowarfare \[[@B2],[@B3]\] included in the Category A of biological agents for public health preparedness against bioterrorism \[[@B4]\]. *Yp*is the etiologic agent of plague, a disease responsible for millions of human deaths during the history of civilization \[[@B5],[@B6]\]. Cases are reported every year in many parts of the world \[[@B7]\] and the increasing number of worldwide cases has placed plague in the category of re-emerging diseases \[[@B8]\].

Patients with plague need prompt antibiotic treatment or else death may be unavoidable. The aminoglycosides streptomycin (STR) and gentamicin (GEN) are the preferred antibiotics for treatment, but a number of other drugs are also effective \[[@B9],[@B10]\]. Tetracyclines \[such as doxycycline (DOX)\], chloramphenicol (CHL), or selected sulfonamides are the recommended antibiotics for prophylactic therapy in the event of exposure or high risk of exposure to *Yp*\[[@B2],[@B9],[@B10]\]. Fluoroquinolones have also been suggested for treatment and prophylaxis and are noted as a chemotherapeutic alternative against strains resistant to the first line anti-plague drugs \[[@B2],[@B10]\].

The threat of bioterrorism-generated plague outbreaks with engineered (multi)drug-resistant *Yp*strains \[[@B2],[@B3]\] and the documented outbreak of multidrug-resistant plague \[[@B11]\] underscore the need to develop alternative chemotherapeutic solutions to this disease. In line with this view, we are exploring the development of anti-infectives that target the high-affinity iron acquisition system of *Yp*\[[@B12]-[@B14]\] and may offer novel therapeutic possibilities \[[@B15]\]. The plague biothreat also underscores the need to increase our understanding of the intrinsic potential of *Yp*for developing antimicrobial resistance and to anticipate the mechanisms of resistance that may emerge in *Yp*clinical isolates in the future. With this consideration in mind, we explored herein the use of a multicopy suppressor screening approach as a means to expose antibiotic resistance determinant candidates in *Yp*. Multicopy suppressor screening has been useful to study potential drug targets or mechanisms of antibiotic resistance in other species \[[@B16]\]. We constructed a multicopy plasmid-based, *Yp*genome-wide expression library of nearly 15,000 clones in *E. coli*(*Ec*), a tractable and easy-to-manipulate surrogate bacterial host, and screened the library for suppressors of the antimicrobial activity of the fluoroquinolone antibiotic ofloxacin (OFX). Noteworthy, fluoroquinolones have been suggested by the Working Group on Civilian Biodefense as alternative drugs in the event of the use of aerosolized *Yp*as a bioweapon against a civilian population \[[@B2]\]. The screen permitted the identification of a gene that reduced the susceptibility of *Yp*to fluoroquinolones and other antibiotic classes when overexpressed from a multicopy plasmid. Our study provides proof of principle for the utilization of multicopy suppressor screening using an *Ec*host as a means to identify antibiotic resistance determinant candidates in *Yp*.

Results and Discussion
======================

A multicopy suppressor screen led to the isolation of a *Y. pestis*genomic fragment involved in ofloxacin resistance
--------------------------------------------------------------------------------------------------------------------

We constructed a plasmid-based expression library of the *Yp*genome comprised of 15,648 *Ec*clones and screened the library for strains with reduced OFX susceptibility. A strain (*Ec*pGEM-OFXr1) selected in the screen exhibiting reduced susceptibility that was confirmed to be plasmid-mediated and transferable to *Yp*was chosen for further characterization (Figure [1](#F1){ref-type="fig"}). The plasmid (pGEM-OFXr1) carried by this strain was isolated and the restriction digestion pattern and sequence of its genomic insert were examined. This analysis revealed a 4,158-bp fragment (*Yp*KIM chromosome coordinates 4,137,482 to 4,141,639) (Figure [2](#F2){ref-type="fig"}). The 5\' and 3\' ends of the fragment included the 5\' end of *y3722*(*creA*) and the 3\' end of *y3727*(*slt*), respectively. The products of *creA*and *slt*are annotated as a conserved hypothetical protein and a putative soluble lytic murein transglycosylase, respectively, in the *Yp*genome database. The center of the fragment encompassed four genes: *y3723*(*robA*, herein referred to as *robA*~Yp~); *y3724*(*gpmB*); *y3725*; and *y3726*(*trpR*). The products of *gpmB*and *trpR*are annotated as a putative phosphoglyceromutase and a putative regulator of tryptophan metabolism genes, respectively. The product of *y3725*is annotated as a conserved hypothetical protein. Our *in silico*search for conserved domains (via CD-Search; please see Availability & requirements for more details) revealed the presence of an NTPase (PRK05074) domain in this protein. The NTPase domain is characteristic of proteins with pyrophosphatase activity \[[@B17],[@B18]\]. This suggested that *y3725*may be involved in nucleoside triphosphate metabolism. Lastly, the predicted product of *robA*~Yp~(RobA~Yp~) is annotated as an orthologue of *Ec*RobA (RobA~Ec~), a transcriptional regulator of unclear physiological function and member of the AraC/XylS family \[[@B19]\]. Importantly, overexpression of *robA*~Ec~and *Enterobacter cloacae robA*confers low-level resistance in *Ec*and *E. cloacae*, respectively, to a number of unrelated antibiotics \[[@B20]-[@B22]\]. Thus, the analysis of the insert in pGEM-OFXr1 suggested that *robA*~Yp~is responsible for the reduced OFX susceptibility observed in *Ec*pGEM-OFXr1 and *Yp*pGEM-OFXr1 (Figure [1](#F1){ref-type="fig"}). These results validate the utility of our library and suppressor screen approach as a means to identify antibiotic resistance determinant candidates in *Yp*.

![**Reduction of ofloxacin susceptibility conferred by plasmids pGEM-OFXr1 and pGEM-Rob~Yp~**. *E. coli*(*Ec*) and *Y. pestis*(*Yp*) strains were streaked on solid media without or with ofloxacin: 0.35 μg/ml (the concentration used in the screen) for *E. coli*and 0.15 μg/ml for *Y. pestis*. Ampicillin (100 μg/ml) was also added to the media for plasmid-carrying strains.](1471-2180-8-122-1){#F1}

![Genetic map of the *robA*~Yp~-containing region of the *Y. pestis*KIM chromosome and inserts of pGEM-OFXr1 and pGEM-Rob~Yp~.](1471-2180-8-122-2){#F2}

Overexpression of *robA*~Yp~affects susceptibility to multiple antibiotics
--------------------------------------------------------------------------

We investigated whether overexpression of *robA*~Yp~alone would reduce OFX susceptibility in *Ec*and, more importantly, in *Yp*. To this end, we evaluated the antibiotic susceptibility of *Ec*pGEM-Rob~Yp~and *Yp*pGEM-Rob~Yp~. These test strains carried pGEM-Rob~Yp~, a plasmid constructed by inserting the fragment encompassing *robA*~Yp~and its promoter region (identified by using the *robA*~Ec~promoter as reference \[[@B23]\]) into the vector pGEM-4Z. The antibiotic susceptibilities of these test strains were compared to that of the corresponding *Ec*pGEM-4Z and *Yp*pGEM-4Z control strains. These control and test strains were isogenic, except for the lack of the plasmid-borne *robA*~Yp~, and their growth in ampicillin (AMP)-containing liquid media was indistinguishable from that of their cognate test strains (not shown). A first examination of *Ec*pGEM-Rob~Yp~and *Yp*pGEM-Rob~Yp~indicated that these strains retained the reduced OFX susceptibility phenotype seen in *Ec*pGEM-OFXr1 and *Yp*pGEM-OFXr1 on solid media (Figure [1](#F1){ref-type="fig"}), thus indicating that *robA*~Yp~alone was sufficient to reduce OFX susceptibility. In view of this, we conducted further OFX susceptibility testing in liquid media. In addition, we compared the susceptibility of the test and control strains to two other fluoroquinolones \[ciprofloxacin (CIP) and levofloxacin (LVX)\], a quinolone (NAL), and antibiotics of other classes, including two tetracyclines \[tetracycline (TET) and DOX\], four aminoglycosides \[STR, GEN, kanamycin (KAN), and apramycin (APR)\], and CHL.

The IC~50~and MIC~99~values determined for the aforementioned antibiotics are shown in Table [1](#T1){ref-type="table"}. Comparison of the OFX IC~50~and OFX MIC~99~values of the test strains and their respective control strains revealed that overexpression of *robA*~Yp~reduced OFX susceptibility in both *Yp*and *Ec*. In *Yp*, *robA*~Yp~overexpression increased OFX IC~50~and OFX MIC~99~values by 5-fold and 23-fold, respectively. The IC~50~and MIC~99~values of CIP, LVX, and NAL also increased significantly (3- to 5-fold change range) in *Yp*pGEM-Rob~Yp~compared with *Yp*pGEM-4Z. The reduced OFX and LVX susceptibility of *Yp*pGEM-Rob~Yp~was also revealed by time-kill experiments described below. In *Ec*, *robA*~Yp~overexpression produced an increase in the IC~50~and MIC~99~of the fluoroquinolone antibiotics (2- to 4-fold change range), but had no significant effect (\<2-fold change) on NAL susceptibility.

###### 

Effect of *robA*~Yp~overexpression on antibiotic susceptibility

                    IC~50~(μg/ml)^a^   FC^c^     MIC~99~(μg/ml)^b^   FC                                          
  ----------------- ------------------ --------- ------------------- ----- ------------ --------- -------------- -----
  Ofloxacin         0.01               0.01      0.05                5     0.03         0.03      0.7            23
  Ciprofloxacin     0.009              0.009     0.04                4     0.02         0.02      0.09           5
  Levofloxacin      0.01               0.01      0.04                4     0.02         0.02      0.09           5
  Nalidixic Acid    0.5                0.8       2                   3     2            2         6              3
  Chloramphenicol   0.3                0.4       0.9                 2     1            1         3              3
  Tetracycline      0.7                1         6                   6     1            3         10             3
  Doxycycline       0.4                0.5       1                   2     0.6          1         3              3
  Kanamycin         1                  0.9       0.4                 0.4   2            2         2              1
  Apramycin         2                  3         1                   0.3   6            6         4              0.7
  Streptomycin      1                  2         0.8                 0.4   3            3         3              1
  Gentamicin        0.4                0.4       0.2                 0.5   1            0.4       0.4            1
                                                                                                                 
  *E. coli*         no plasmid         pGEM-4Z   pGEM-Rob~Yp~              no plasmid   pGEM-4Z   pGEM-Rob~Yp~   
                                                                                                                 
  Ofloxacin         0.03               0.04      0.09                2     0.08         0.2       0.4            2
  Ciprofloxacin     0.01               0.009     0.04                4     0.05         0.08      0.2            3
  Levofloxacin      0.04               0.04      0.1                 3     0.2          0.2       0.4            2
  Nalidixic Acid    27                 26        28                  1     83           100       100            1
  Chloramphenicol   0.3                0.3       0.8                 3     2            2         13             7
  Tetracycline      0.8                0.6       2                   3     3            3         10             3
  Doxycycline       0.3                0.2       0.6                 3     1            0.6       3              5
  Kanamycin         2                  1         2                   2     10           6         6              1
  Apramycin         3                  3         4                   1     21           17        21             1
  Streptomycin      3                  2         3                   2     17           13        13             1
  Gentamicin        0.9                0.6       2                   3     6            5         8              2

^a^IC~50~values were calculated from sigmoidal curves fitted to triplicate sets of dose-response data. ^b^MIC~99~values are means of triplicates. ^c^Fold change (FC) values were calculated as the ratio of the IC~50~or MIC~99~of the pGEM-Rob~Yp~transformants to the IC~50~or MIC~99~of the pGEM-4Z transformants. IC~50~, MIC~99~, and FC values \<1 and values \>1 were rounded to one significant digit and to the nearest non-fractional number, respectively.

In both *Yp*and *Ec*, *robA*~Yp~overexpression also correlated with an increase in the IC~50~and MIC~99~of the two tetracyclines tested and CHL (2- to 7-fold change range). No substantial impact (\<2-fold change) on the MIC~99~values of four aminoglycosides tested was detected in *Yp*upon overexpression of *robA*~Yp~. Interestingly, however, the IC~50~values of these aminoglycosides were reproducibly and consistently lower (2- to 3-fold reduction range) in *Yp*pGEM-Rob~Yp~compared with *Yp*pGEM-4Z. These results indicated that *robA*~Yp~overexpression increased the susceptibility of *Yp*to aminoglycosides. The hypersensitivity of *Yp*pGEM-Rob~Yp~to aminoglycosides was also observed in time-kill experiments described below. Aminoglycoside hypersensitivity was not observed in *Ec*pGEM-Rob~Yp~. On the contrary, the strain had a modest decrease in the susceptibility to GEN, STR, and KAN (2- to 3-fold change range) relative to *Ec*pGEM-4Z.

Overall, the phenotypic comparison of the antibiotic susceptibility of pGEM-Rob~Yp~*-*bearing strains and pGEM-4Z-bearing strains clearly demonstrates that *robA*~Yp~overexpression affects antibiotic susceptibility in both *Yp*and *Ec*, yet in a noticeably species-specific manner. As discussed below, the effects on antibiotic susceptibility induced by *robA*~Yp~overexpression are likely due to an upregulation of efflux pumps. Thus, the species-specific differences in antibiotic susceptibility are probably produced by species-specific differences in efflux pump upregulation.

Overexpression of *robA*~Yp~in *Y. pestis*reduces killing by fluoroquinolones but enhances killing by aminoglycosides
---------------------------------------------------------------------------------------------------------------------

The comparative analysis of IC~50~and MIC~99~values described above indicated that *Yp*pGEM-Rob~Yp~has reduced fluoroquinolone susceptibility and increased aminoglycoside susceptibility compared with *Yp*pGEM-4Z. To further probe these phenotypes, we examined the killing kinetics of these two strains when exposed to OFX, CIP, STR, and GEN (Figure [3](#F3){ref-type="fig"}). The profiles of the time-kill curves for OFX and CIP demonstrated that the *Yp*pGEM-4Z control was more rapidly killed by the fluoroquinolones than *Yp*pGEM-Rob~Yp~. Conversely, the profiles of the time-kill curves for STR and GEN revealed that *Yp*pGEM-Rob~Yp~was more rapidly killed by the aminoglycosides than the *Yp*pGEM-4Z control. Both strains had comparable growth in the absence of fluoroquinolone or aminoglycoside antibiotics during the time frame of the time-kill assays. The contrasting effects of *robA*~Yp~overexpression on fluoroquinolone- and aminoglycoside-mediated killing are consistent with the results of the comparative analysis of IC~50~and MIC~99~values (Table [1](#T1){ref-type="table"}). The observed aminoglycoside hypersensitivity is somewhat unexpected and contrasts with both the reduced susceptibility observed for all other antibiotics tested and the increased tolerance to organic solvents described below.

![**Effect of *robA*~Yp~overexpression on the rate of *Y. pestis*killing by fluoroquinolones and aminoglycosides**. *Yp*pGEM-Rob~Yp~(overexpressing *robA*~Yp~) and *Yp*pGEM-4Z (vector control) were treated with the indicated antibiotics at 5 × MIC~99~. The means of triplicate treated cultures were plotted and standard error bars are shown.](1471-2180-8-122-3){#F3}

Overexpression of *robA*~Yp~increases tolerance to organic solvents
-------------------------------------------------------------------

We investigated whether *robA*~Yp~overexpression affected the susceptibility of *Yp*and *Ec*to O~2~^.-^-generating compounds (paraquat, menadione, and plumbagin), heavy metals (zinc, cobalt, and copper), and organic solvents (*n*-pentane, *n*-hexane, cyclohexane, *p*-xylene, and diphenyl ether). No effect on the susceptibility to O~2~^.-^-generating compounds, cobalt, and copper was observed (not shown). Conversely, overexpression of *robA*~Yp~drastically increased organic solvent tolerance in both *Yp*and *Ec*(Figure [4](#F4){ref-type="fig"}) and reduced the susceptibility of *Yp*to zinc (not shown). Overexpression of *robA*~Yp~increased the tolerance of *Yp*to *n*-hexane and cyclohexane and the tolerance of *Ec*to cyclohexane and *n*-pentane. All the *Yp*and *Ec*strains were resistant to diphenyl ether and sensitive to *p*-xylene. *Ec*was also resistant to *n*-hexane, a result that is in agreement with previous reports \[[@B24]\]. These findings parallel the reduction of organic solvent susceptibility induced by *robA*~Ec~overexpression in *Ec*\[[@B21]\].

![**Effect of *robA*~Yp~overexpression on organic solvent tolerance**. Cultures of *Y. pestis*(*Yp*) and *E. coli*(*Ec*) strains carrying the plasmids indicated were spotted on solid medium. The surface of the medium was overlaid with the organic solvent and growth was recorded after incubation. H, *n*-hexane; CH, cyclohexane; P, *n*-pentane; X, *p*-xylene; DE, diphenyl ether; -, no solvent control.](1471-2180-8-122-4){#F4}

Overexpression of *robA*~Yp~in *Y. pestis*induces changes in efflux pump gene expression
----------------------------------------------------------------------------------------

In *Ec*, the RobA~Ec~-induced multidrug resistance and solvent tolerance phenotypes have been shown to be largely dependent on the upregulation of the multidrug efflux pump AcrAB, which belongs to the resistance-nodulation-cell division (RND) superfamily \[[@B25],[@B26]\]. With this precedent in mind, we compared the expression of genes belonging to 34 drug efflux pumps between *Yp*pGEM-Rob~Yp~and *Yp*pGEM-4Z using quantitative real-time PCR (qRT-PCR). These pumps were identified using a variety of bioinformatic approaches (see Methods) to compile an extensive list that included most, if not all, putative drug efflux pump systems encoded in the genome of *Yp*. It is worth mentioning as a reference that there are 37 drug efflux pumps annotated in the *Ec*genome \[[@B27],[@B28]\]. Our expression analysis detected transcripts for 33 of the 34 genes investigated and revealed that four efflux pumps were significantly upregulated (≥ 5-fold change) in *Yp*pGEM-Rob~Yp~compared with *Yp*pGEM-4Z (Table [2](#T2){ref-type="table"}). Interestingly, two of these upregulated pumps (*y3392-y3393*and *y1050-y1049*) are *Ec*AcrAB homologs. The other two upregulated pumps (*y2173*and *y0010*) belong to the major facilitator superfamily (MFS). The transcript level of *hasF*(*y3516*), encoding the ortholog of *Ec*TolC, which is the outer membrane protein channel that partners with *Ec*AcrAB and other RND and MFS pumps \[[@B29],[@B30]\], was drastically upregulated as well (5.8-fold change; not shown).

###### 

Effect of *robA*~Yp~overexpression on the transcript levels of efflux pump genes in *Y. pestis*

  Gene name^a^              University of Wisconsin^b^    TIGR         SANGER    Pump family or protein function^c^   FC^d^
  ------------------------- ----------------------------- ------------ --------- ------------------------------------ ----------------
  (*floR*)                  *y2173*                       NT02YP2579   YPO2148   MFS                                  **12.7 ± 2.5**
  (*yieO*)                  *y0010*                       NT02YP0010   YPO0009   MFS                                  **8.6 ± 1.1**
  (*acrA\*-acrB*)           *y3392\*-y3393*               NT02YP4041   YPO1000   RND                                  **6.9 ± 0.4**
  *acrA\*-acrB*             *y1050\*-y1049*               NT02YP1227   YPO3132   RND                                  **5.0 ± 0.4**
  (*acrA\*-acrB*)           *y3760\*-y3759*               NT02YP4463   YPO0420   RND                                  2.7 ± 0.1
  *-*                       *y4041*                       NT02YP4789   YPO4020   DMT                                  1.7 ± 0.9
  *yegM\*-yegN-yegO-yegB*   *y1386\*-y1385-y1384-y1383*   NT02YP1646   YPO2847   RND                                  1.4 ± 0.5
  (*ybjY\*-ybjZ*)           *y2814\*-y2813*               NT02YP3366   YPO1364   ABC                                  1.4 ± 0.4
  (*acrA\*-acrB*)           *y0702\*-y0703*               NT02YP0804   YPO3483   RND                                  1.3 ± 0.3
  *emrA\*-emrB*             *y0922\*-y0921*               NT02YP1066   YPO3267   MFS                                  1.3 ± 0.4
  (*macA\*-macB*)           *y1481\*-y1480*               NT02YP1756   YPO2999   RND                                  1.3 ± 0.5
  *ygeD*                    *y3180*                       NT02YP3786   YPO0792   MFS                                  1.3 ± 0.2
  *fieF*                    *y0060*                       NT02YP0067   YPO0077   CDF                                  1.2 ± 0.1
  (*abgT*)                  *y3402*                       NT02YP4052   YPO1008   IT                                   1.1 ± 0.2
  *acrD*                    *y1439*                       NT02YP1705   YPO3043   RND                                  1.1 ± 0.1
  *sugE*                    *y0613*                       NT02YP0702   YPO0355   SMR                                  1.1 ± 0.4
  (*ynfM*)                  *y2108*                       NT02YP2497   YPO2266   MFS                                  1.1 ± 0.4
  *bcr*                     *y2916*                       NT02YP3488   YPO1267   MFS                                  1.1 ± 0.3
  *aaeA\*-aaeB*             *y0178\*-y0177*               NT02YP0192   YPO3685   ArAE                                 1.1 ± 0.0
  (*yjcR\*-Q*)              *y3558\*-y3559*               NT02YP4231   YPO0619   RND                                  1.0 ± 0.2
  *yajR*                    *y1017*                       NT02YP1187   YPO3169   MFS                                  1.0 ± 0.1
  *arsB*                    *y0844*                       NT02YP0968   YPO3347   IT                                   1.0 ± 0.4
  *corC*                    *y1191*                       NT02YP1397   YPO2617   HCC                                  0.9 ± 0.1
  *mdtJ\*-mdtI*             *y2242\*-y2241*               NT02YP2670   YPO2068   SMR                                  0.8 ± 0.2
  *rosA*                    *y1087*                       NT02YP1268   YPO3093   MFS                                  0.8 ± 0.1
  *ydhC*                    *y1948*                       NT02YP2306   YPO2389   MFS                                  0.8 ± 0.2
                            *y3186*                       NT02YP3792   YPO0798   MFS                                  0.7 ± 0.1
  (*ydhE*)                  *y1945*                       NT02YP2302   YPO2392   MATE                                 0.7 ± 0.1
  (*ybeQ*)                  *y1874*                       NT02YP2220   YPO1712   MFS                                  0.7 ± 0.0
  *mdlA\*-mdlB*             *y1039\*-y1040*               NT02YP1213   YPO3145   ABC                                  0.7 ± 0.0
  *ydeF*                    *y2653*                       NT02YP3168   YPO1515   MFS                                  0.5 ± 0.1
  *emrE, gacE*              *y2000*                       NT02YP2368   YPO2333   SMR                                  0.5 ± 0.0
  *mdfA, cmr*               *y4067*                       NT02YP4824   YPO4048   MFS                                  0.2 ± 0.0
  (*ydjV*)                  *y2272*                       NT02YP2703   YPO2040   MFS                                  nd

^a^Gene name as annotated for *Y. pestis*strain KIM and/or CO92 or gene names (in parentheses) given herein based on the name of their *E. coli*homologs. Multiple names for the same gene are separated by commas. Genes of multi-component pumps are separated by dashes. The star (\*) marks genes from multi-component pump gene clusters whose transcripts were analyzed by qRT-PCR. ^b^Gene designations in the University of Wisconsin, TIGR, and SANGER *Y. pestis*genome databases. The Wisconsin column shows designations for all the genes in each predicted multi-component pump. TIGR and SANGER columns show only genes targeted in qRT-PCR. ^c^Pump families assigned based on homology to known (super)family members from other organisms. MFS, major facilitator superfamily; SMR, small multidrug resistance family; ABC, ATP-binding cassette superfamily; RND, resistance-nodulation-cell division superfamily; MATE, multidrug and toxic compound extrusion family; DMT, drug/metabolite transporter superfamily; CDF, cation diffusion facilitator family; ArAE, aromatic acid exporter family; IT, Ion transporter superfamily; HCC, HlyC/CorC family. ^d^Fold change values (FC) are means of triplicates ± standard errors and are presented in decreasing order. For polycistronic transcripts, qRT-PCR was conducted with primers targeting the first pump component-encoding gene of the operon. These genes are marked with a star. nd, transcript not detected in any of the three *Y. pestis*strains examined (wild-type, *Yp*pGEM-4Z, and *Yp*pGEM-Rob~Yp~).

Inspection of the promoter regions upstream of the upregulated genes in *Yp*pGEM-Rob~Yp~revealed the presence of a putative RobA~Ec~binding site in each of these regions (Figure [5](#F5){ref-type="fig"}). These results suggest that RobA~Yp~may act as a positive regulator for the *y0010, y1050-y1049*, *y2173*and *y3392-y3393*systems. This possible regulatory scenario is consistent with the upregulation in the expression levels of these pumps induced by *robA*~Yp~overexpression in *Yp*.

![**Potential RobA binding sites in the promoter regions of genes upregulated in *robA*~Yp~-overexpressing *Y. pestis***. The consensus shown is the 20-bp asymmetric *marbox*consensus sequence determined by Martin *et al*., 1999 \[[@B37]\]. R = A or G, Y = C or T, W = A or T, and N = A, T, G, C. Column C is the number of bp\'s in agreement with the 20-bp consensus sequence. The location of each RobA binding site with respect to the first codon of its cognate gene is indicated by the numbers flanking the putative binding site.](1471-2180-8-122-5){#F5}

It is likely that the multidrug resistance and solvent tolerance phenotypes induced by *robA*~Yp~overexpression are due, at least in part, to increases in compound extrusion by one or more of the upregulated pumps mentioned above. This idea is supported by the reported observation that the RobA~Ec~-induced multidrug resistance and solvent tolerance in *Ec*is largely dependent on the AcrAB-TolC efflux pump system \[[@B25],[@B26]\].

Conclusion
==========

The identification of *Yp*genes that, when overexpressed, are capable of reducing antibiotic susceptibility is a useful strategy to expose genes that this pathogen may rely upon to evolve resistance via a vertical modality. In this study, we explored the use of a multicopy suppressor, *Ec*host-based screening approach as a means to identify antibiotic resistance determinant candidates in *Yp*. To seek proof of principle for this approach, we constructed a multicopy plasmid-based, *Yp*genome-wide expression library of nearly 16,000 clones in *Ec*and screened this library for suppressors of the antimicrobial activity of the fluoroquinolone antibiotic OFX. The screen permitted the identification of a gene that, when overexpressed, reduces the susceptibility of *Yp*not only to OFX, but also to other (fluoro)quinolones, tetracyclines and CHL. This gene (*robA*~Yp~) encodes a putative transcriptional regulator, and our results clearly demonstrate that its overexpression in *Yp*and *Ec*confers low-level resistance to multiple antibiotics. Overexpression of *robA*~Yp~also increases organic solvent tolerance in both *Yp*and *Ec*and reduces the susceptibility of *Yp*to zinc.

The molecular mechanism by which overexpression of *robA*~Yp~leads to a reduction in the susceptibility to antibiotics and other compounds remains to be determined. Our results indicate that overexpression of *robA*~Yp~induces a drastic upregulation in the transcript levels of four of the 34 predicted efflux pump gene systems and of *hasF*(*tolC*) in *Yp*. Increased expression of chromosomally encoded efflux pumps is a known cause of multidrug resistance in many bacteria \[[@B30]\]. Thus, it is likely that the reduction in the susceptibility to antibiotics and other compounds induced by *robA*~Yp~overexpression is due, at least in part, to multidrug efflux pump-mediated increases in compound extrusion.

Overall, our findings provide proof of principle for the utilization of an *Ec*host-based suppressor screen to identify antibiotic resistance determinant candidates in *Yp*. This methodology will be useful in the identification of genetic determinants involved in target-dependent and target-independent resistance to antimicrobials with known and unknown mechanisms of action. Identification of such genetic determinants will provide first insights to guide further studies to obtain mechanistic information on novel modes of antimicrobial activity and antimicrobial resistance.

Methods
=======

Construction of genomic library
-------------------------------

Unless otherwise indicated, all molecular biology and microbiological manipulations were conducted using standard procedures \[[@B31]\] and reagents acquired from New England Biolabs or Sigma-Aldrich. Genomic DNA from the avirulent *Yp*strain KIM6+ \[[@B32]\] was used for the library. This strain lacks the Lcr virulence plasmid \[[@B5]\] and is excluded from the Select Agent Program (please see Availability & requirements for more details). Genomic DNA was prepared using AquaPure™ Genomic DNA Isolation Kit (Bio-Rad Laboratories) and partially digested with *Bsr*FI, which, on average, cleaves the genome of *Yp*every \~760 bp. Independent partial digestions were resolved by agarose gel electrophoresis and the fragment populations in the 4,000-bp to 8,000-bp range were purified using QIAquick Gel Extraction Kit (Qiagen). The fragments were ligated to the multicopy plasmid vector pGEM-4Z (Promega) linearized with *Xma*I and dephosphorylated with calf intestine alkaline phosphatase. Genes inserted into pGEM-4Z can be transcribed from the *gpt-lac*hybrid promoter located at the 5\'-end of the cloning site and, potentially, from their native promoters. Ligations were transformed into *Ec*DH5α (Invitrogen) and transformants were selected in Luria-Bertani (LB) agar plates containing AMP (100 μg/ml) and 5-bromo-4-chloro-3-indolyl-β-[D]{.smallcaps}-galactopyranoside (40 μg/ml) for blue/white colony screening \[[@B31]\]. White colonies were streaked onto the same medium to verify their white phenotype and 15,648 confirmed white clones were independently grown in AMP-containing LB broth in 96-well plates. After plate incubation for culture growth to early stationary phase, aliquots from each of the 96 cultures of each plate were pooled, cells from each pool were harvested, and plasmids from each pool were purified using QIAprep Spin Miniprep Kit (Qiagen). The cultures in the plates were supplemented with glycerol (25%) and this master library was stored at -70°C. Agarose gel electrophoresis analysis confirmed plasmid population heterogeneity and restriction digestion analysis of plasmids from several clones verified insert diversity (not shown). The library provides a theoretical \~760-fold genome coverage. Our *in silico Bsr*FI restriction analysis of the *Yp*genome revealed the presence of four *Bsr*FI fragments of ≥ 8,000 bp. These fragments, which add up to 39,118 bp, are unlikely to be represented in the library.

Multicopy suppressor screening
------------------------------

The library was replicated using a 96-pin inoculator (Clonemaster™; Immusine Laboratories, Inc.) to inoculate 96-well plates loaded with fresh culture medium (150 μl/well). After plate incubation for culture growth (9 h, 37°C, 200 rpm), the 15,648 cultures were pooled and the cells of the pool were harvested. The pooled cells were resuspended in fresh medium (1/10 × pool\'s volume) containing AMP (100 μg/ml) and glycerol (25%), and the suspension was aliquoted (1 ml library stock aliquots) and stored at -70°C. Multicopy suppressor gene-containing clones were screened for by plating a 1/100 dilution of a library stock aliquot on LB agar plates containing AMP (100 μg/ml) and OFX at the MIC (0.35 μg/ml). The OFX MIC was determined by plating *Ec*carrying pGEM-4Z (*Ec*pGEM-4Z) on LB agar plates containing AMP (100 μg/ml) and OFX at increasing concentrations and defined as the concentration for which no colonies were obseved after plate incubation (37°C, 48 h). Clones identified in the screen were streaked on plates containing AMP (100 μg/ml) and OFX (0.35 μg/ml) to confirm their resistant phenotype. The plasmid from each confirmed clone was isolated and transformed into *Ec*and *Yp*. Each transformant was streaked on AMP and OFX-containing plates \[LB agar for *Ec*and tryptose blood agar base (TBA; Difco Laboratories) for *Yp*\] to ascertain whether the resistance was plasmid mediated. The insert of each plasmid conferring resistance was sequenced using M13 forward and reverse universal primers (Invitrogen). The sequences obtained were used as queries in sequence similarity searches against the *Yp*KIM genome using BLAST (please see Availability & requirements for more details) to determine the genome fragment carried by the plasmid.

Construction of pGEM-Rob~Yp~and transformation of *Y. pestis*
-------------------------------------------------------------

The fragment encompassing *Yp robA*(herein referred to as *robA*~Yp~) and its promoter region was PCR-amplified from plasmid pGEM-OFXr1 (see results) with primers Robfor1 and Robrev1 (Table [3](#T3){ref-type="table"}). The PCR product (1030 bp) was cloned into pCR2.1-TOPO (TOPO TA Cloning Kit, Invitrogen) and the fidelity of the insert was verified by DNA sequencing. The insert was recovered from the pCR2.1-TOPO clone as an *Eco*RI fragment and sub-cloned into the *Eco*RI site of pGEM-4Z using *Ec*DH5α as host. A clone with *robA*~Yp~in the same orientation as the *lacZ*gene of pGEM-4Z was designated pGEM-Rob~Yp~. pGEM-Rob~Yp~and pGEM-4Z were introduced into avirulent *Yp*by electroporation as reported earlier \[[@B33]\] to create strains *Yp*pGEM-Rob~Yp~and *Yp*pGEM-4Z, respectively. *Yp*strains were grown in heart infusion broth (HIB; Difco Laboratories) and on TBA plates without or with antibiotics as appropriate.

###### 

Oligonucleotides used in this study

  **Name^a^**   **Sequence**
  ------------- -----------------------------------------
  Robfor1       5\'-TCTAGACGCTTTTTAACACACTGTACCAGT-3\'
  Robrev1       5\'-GAATTCATTTAGATATGCCAGCACTTGATGA-3\'
  16sRNAF       5\'-ATGACCAGCCACACTGGAACTGA-3\'
  16sRNAR       5\'-TGACTTAACAAACCGCCTGCGT-3\'
  y3392F        5\'-AGCGGCACCTTGGTCAATATTGT-3\'
  y3392R        5\'-CAATTTGGTTATCCACCGATTCA-3\'
  y1050F        5\'-GCTTATGACAGTGCAAAAGGTGA-3\'
  y1050R        5\'-GATTAATGCGTGCAGACTCCAGT-3\'
  y0702F        5\'-TATACCCAAGTGCGGGCACCCAT-3\'
  y0702R        5\'-CATTCGCTACTGTGTCATTGCCT-3\'
  y3402F        5\'-TCGATGCCACTGAATAGCGATCT-3\'
  y3402R        5\'-ATCTGGTGAACGCAATAACGAGT-3\'
  y1439F        5\'-CAGCCATCAAGAGGCTGCCCCAA-3\'
  y1439R        5\'-ACCAAAGGCATCGACGCTGCCGA-3\'
  y1087F        5\'-GGTGCTATCAGCGTATCTCACCT-3\'
  y1087R        5\'-CCATACCGATGGGTAATGAGTAT-3\'
  y0060F        5\'-GCAACCTGCTGATGAAGAACATA-3\'
  y0060R        5\'-CACGAATCGCCTGACTGTGTGTT-3\'
  y0844F        5\'-CGTTGCTAAACCGACTGGGTGAA-3\'
  y0844R        5\'-TTGCGACAAAACATGCAGCCACA-3\'
  y0922F        5\'-CGGCAGTGTGGTCAGTGTTCATT-3\'
  y0922R        5\'-CACCCGACGCTTCAGGTCATTTT-3\'
  y1191F        5\'-TCCTTAACCAGCTCTTCCACGGT-3\'
  y1191R        5\'-CTTTATCTTCGCTGATCACCGGA-3\'
  y1386F        5\'-GTGGTCAGGACACTAGCCATGGT-3\'
  y1386R        5\'-CCTGCGTCAGTTGGACTTCGTAA-3\'
  y1481F        5\'-AAAGCACAGAAGCAGGTGACTGT-3\'
  y1481R        5\'-TTGTTGCTGACGCTGGTAGGTGA-3\'
  y1874F        5\'-TTACCGACTATCGCACGTGACCT-3\'
  y1874R        5\'-TTGTAGCACACGGGCAAACGTCA-3\'
  y1945F        5\'-CCTGATGATGAGATGGTACGTAA-3\'
  y1945R        5\'-TGAACTGAAGTTGAGGGCAATCT-3\'
  y2242F        5\'-TTTAGTGACACTGATTGGTGGGA-3\'
  y2242R        5\'-CATGATGCTCACCTGACTCAACA-3\'
  y3180F        5\'-GGTAATGATGGTGGCTAATGGTT-3\'
  y3180R        5\'-CAACCGAGCCAAGTAAGATCGCA-3\'
  y3558F        5\'-GCCATTGATCCTGTTATCGGCTA-3\'
  y3558R        5\'-ATAGGGAACAGATGAATGCCACA-3\'
  y4041F        5\'-TTACGACCACAACGGTAGATGAA-3\'
  y4041R        5\'-CATTGGTGCGGCAAGGTTCATAT-3\'
  y4067F        5\'-GATATGATCCAGCCAGGTATGCT-3\'
  y4067R        5\'-GCACCGATAAAGCACAAGCCAAT-3\'
  y0010F        5\'-TCGCCGAAAGCCTTAACCGTTCT-3\'
  y0010R        5\'-CCGAGAACGCACTAAGAAAGCCA-3\'
  y0178F        5\'-TTTACCGCAGACGTGGTCGCTAT-3\'
  y0178R        5\'-CCTACTGGACTCCCGTTGCTTCT-3\'
  y0613F        5\'-GGGCTATTGGCCTGAAGTATTCT-3\'
  y0613R        5\'-AAGCTTAGTATCCGCGCCAGACT-3\'
  y1017F        5\'-AAATGACTCCGCTAGAGCTTCGA-3\'
  y1017R        5\'-GGTTTACGACCGATACGATCAGA-3\'
  y1039F        5\'-GCCGTGAATGGCACCGTTATGTA-3\'
  y1039R        5\'-AGTTTGCCGACTCAGCTGACGAT-3\'
  y1948F        5\'-CTGCCTGTAGTGCTGGCTTCTTT-3\'
  y1948R        5\'-AGTACAGGGCAATCATGCTGCCA-3\'
  y2000F        5\'-TGGCGATTATTGCCGAAGTGGTT-3\'
  y2000R        5\'-AAAGGTGGCAGCGATTGAGACCA-3\'
  y2108F        5\'-GGTTGTATATCAGCGGTAGTTCT-3\'
  y2108R        5\'-TTGCACGAAAGTGTTTAGACGCT-3\'
  y2173F        5\'-ACAAGGTGTCTCGGTATGCTGCA-3\'
  y2173R        5\'-ATAATGCCAGGAACCAGAACGCT-3\'
  y2272F        5\'-TTGGTATCGCAAGCTCGAAGCTT-3\'
  y2272R        5\'-TCGCATTAGCATCCCGGTGACAA-3\'
  y2653F        5\'-ATGACCGTCAATGCGACCATCGT-3\'
  y2653R        5\'-AATGGCCATTGCCAGCATCCATA-3\'
  y2814F        5\'-TCTGGACCAGGCAGTAACCGATT-3\'
  y2814R        5\'-TACTCATATCGGCCAGGGTCAGA-3\'
  y2916F        5\'-CCTTGGGTTGTTGTCGATGCTGA-3\'
  y2916R        5\'-ACATGCCATACCTGCAAGCGCAA-3\'
  y3186F        5\'-GTCAGTTGGACGTTACTGCTAAT-3\'
  y3186R        5\'-CTTTCTTGCCATAAGCGACGACA-3\'
  y3760F        5\'-TCTGGATATTCGCCGTGCAGAGA-3\'
  y3760R        5\'-CGTGGTAAACAGACGCTCTGGAA-3\'
  y3516F        5\'-TGCAACGACTAACCTGTATCAGT-3\'
  y3516R        5\'-TTTGGCGAGTAGTATTCTCTGGT-3\'

^a^Primers used for qRT-PCR were named according to the University of Wisconsin gene designations for the *Y. pestis*KIM genome, except for 16sRNAF-R (used to amplify 16s rRNA).

MIC~99~and IC~50~determinations
-------------------------------

Dose-response experiments were done in triplicate and using 96 well plate-based microdilution assays as reported \[[@B12],[@B14]\]. Briefly, wells contained 200 μl of broth (LB for *Ec*, HIB for *Yp*) inoculated with 10^4^cfu/ml and supplemented with AMP (100 μg/ml) and a second antimicrobial compound at the concentration indicated below. Antimicrobial compounds were added from stock solutions in water, ethanol, or DMSO. Control cultures lacking the antimicrobial compounds contained water (2%), ethanol (1%), or DMSO (0.5%). After incubation (37°C, 200 rpm, 24 h for *Yp*and 16 h for *Ec*), growth was measured as optical density (*A*~620~) using a Spectra Max Plus spectrophotometer plate reader (Molecular Dynamics). IC~50~values were calculated from sigmoidal curves fitted to triplicate sets of dose-response data using KaleidaGraph (Synergy Software). MIC~99~values were calculated as the lowest concentration tested that inhibited growth by ≥ 99%. The range of concentrations tested were: OFX (Sigma), 2.5-0.001 μg/ml; KAN (Shelton Scientific), 50-0.024 μg/ml; CHL (Calbiochem), 10-0.005 μg/ml for *Yp*and 25-0.012 μg/ml for *Ec*; TET (Sigma), 40-0.020 μg/ml; APR (Sigma), 50-0.024 μg/ml; NAL (Sigma), 25-0.012 μg/ml for *Yp*and 400-0.195 μg/ml for *Ec*; STR (Sigma), 50-0.024 μg/ml for *Yp*and 100-0.049 μg/ml for *Ec*; GEN (EM Science), 25-0.012 μg/ml for *Yp*and 50-0.024 μg/ml for *Ec*; DOX (Sigma), 10-0.005 μg/ml; CIP (Fluka), 0.75-0.0004 μg/ml for *Yp*and 1.25-0.0006 μg/ml for *Ec*; LVX (Fluka), 0.75-0.0004 μg/ml for *Yp*and 1.25-0.0006 μg/ml for *Ec*; plumbagin (Sigma), 50-0.024 μg/ml for *Yp*and 200-0.098 μg/ml for *Ec*; menadione (Sigma), 50-0.024 μg/ml for *Yp*and 400-0.195 μg/ml for *Ec*; paraquat (Sigma), 200-0.098 μg/ml for *Yp*and 400-0.195 μg/ml for *Ec*; CoCl~2~(Sigma), 1-0.0005 mg/ml; CuSO~4~(Sigma), 2-0.001 mg/ml for *Yp*and 4-0.002 mg/ml for *Ec*; ZnCl~2~(Sigma), 1-0.0005 mg/ml.

Organic solvent tolerance assay
-------------------------------

The test for solvent tolerance was conducted essentially as reported previously \[[@B21]\]. Overnight cultures of *Ec*and *Yp*strains grown in LB broth and HIB, respectively, were inoculated (1%) into fresh media and allowed to grow to *A*~620~= 0.4. Then, 5 μl of each culture were spotted on solid medium (LB agar for *Ec*, TBA for *Yp*) with 100 μg/ml AMP for transformants carrying pGEM plasmids or without antibiotic for other strains. The surface of the medium was then overlaid with the organic solvent (7 ml) to a thickness of \~3 mm. The plates were sealed and incubated for 24 h for *Ec*strains and 48 h for *Yp*strains before naked-eye examination for bacterial growth.

Time-kill experiments
---------------------

*Yp* pGEM-Rob~Yp~and *Yp*pGEM-4Z (control) were treated with STR, GEN, OFX, or CIP at 5 × MIC~99~. The MIC~99~values were those determined using *Yp*pGEM-4Z in the dose-response experiments above (5 × MIC~99~values: STR, 15.6 μg/ml; GEN, 5.2 μg/ml; OFX, 0.17 μg/ml; CIP, 0.12 μg/ml). For each antibiotic tested, three tubes with 10 ml of preheated (37°C) HIB containing AMP (100 μg/ml) were inoculated with 10 μl of an overnight culture of the corresponding *Yp*strain and incubated at 37°C with shaking at 200 rpm for 2 h. After incubation, a sample of each culture was taken and cfu/ml were determined by plating serial dilutions on TBA plates containing AMP (100 μg/ml) and enumerating colonies after plate incubation. Immediately after culture sampling, the test antibiotic was added (from stock solutions in water for GEN and STR or stock solutions in DMSO for OFX and CIP) and the cultures were returned to incubation (37°C, 200 rpm). Samples from these cultures were then taken at time points 0 (immediately after antibiotic addition), 30, 60, 90, 120, 180, 240, 300, 360, and 420 min for cfu/ml determination as above. Triplicate control cultures where water or DMSO was added in place of the antibiotic solution were included in the experiments and treated and analyzed in the same way as the antibiotic-treated cultures. The time-kill data were plotted using Kaleidagraph (Synergy software).

Isolation of total RNA and qRT-PCR
----------------------------------

*Yp*and *Ec*were cultured in HIB and LB broth, respectively. AMP (100 μg/ml) was added to the medium for strains carrying pGEM-Rob~Yp~or pGEM-4Z. Cultures were incubated (37°C, 200 rpm) until they reached *A*~620~of \~0.5 before RNA was isolated using the RiboPure-Bacteria Kit (Ambion) according to the manufacturer\'s instructions. RNA was isolated from triplicate cultures and treated with DNase I (Ambion) (4 units, 37°C, 30 min) in DNase I Buffer (Ambion). After the treatment, DNase I was inactivated by adding DNase Inactivation Reagent (Ambion) at 20% of the final volume of RNA treated. The inactivation was allowed to proceed at room temperature for 2 min. The RNA sample was then centrifuged at maximum speed in a microcentrifuge for 1 min to pellet the inactivation reagent. The RNA was then transferred to a new RNase-free microcentrifuge tube. cDNA was prepared from each RNA sample using TaqMan^®^Reverse Transcription Reagents Kit (Applied Biosystems) according to the manufacturer\'s instructions. Each cDNA sample was analyzed in triplicate by qRT-PCR using SYBR^®^Green Master Mix (Applied Biosystems) according to the manufacturer\'s instructions. cDNA was kept undiluted for qRT-PCR analysis of *robA*cDNA and diluted 1:5 for analysis of other cDNAs. qRT-PCR and target sequence relative quantification were carried out using a 384-multiwell platform with an ABI-PRISM 7900 HT Sequence Detection System (Applied Biosystems) as described previously \[[@B34],[@B35]\]. The thermocycling program included 1 cycle of 95°C for 5 min followed by 40 cycles of 95°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min. Relative quantification was conducted using the standard equation 2^-ΔΔCT^{*i.e*. 2^-\ \[(CT\ of\ target\ cDNA\ in\ sample1-CT\ of\ 16S\ rRNA\ cDNA\ in\ sample\ 1)-(CT\ of\ target\ cDNA\ in\ sample\ 2-CT\ of\ 16S\ rRNA\ cDNA\ in\ sample\ 2)\]^} \[[@B36]\]. The equation expresses n-fold difference of the target cDNA in the sample from the strain carrying pGEM-Rob~Yp~(sample 1) relative to the target cDNA in the sample from the strain carrying pGEM-4Z (sample 2, control) with normalization to an endogenous control (16S rRNA cDNA). The cycle threshold (CT) values utilized in the equation were the average of three independent cultures of the same strain, each analyzed in triplicate by qRT-PCR.

Identification of putative drug efflux pumps and RobA~Yp~binding sites
----------------------------------------------------------------------

Searches for efflux pumps were conducted in the sequenced genomes of *Yp*KIM and and *Yp*CO92 (please see Availability & requirements for more details). The search included the following strategies. First, the tables of functional classes in the genome websites were examined for annotated pumps. Second, the navigator function in the Artemis genome viewer software (please see Availability & requirements for more details) was used to search for the terms multidrug, efflux, transport, translocase, pump, and drug resistance as qualifiers in the annotated genome sequences. Third, the names of annotated *Ec*multidrug efflux pumps were used as search keywords using the navigator function in Artemis to find potential pumps not yet identified with the other strategies. Fourth, all putative pumps identified in *Yp*KIM were used as queries in BLASTP-based searches against the *Yp*CO92 genome and *vice versa*. Fifth, annotated *Ec*multidrug efflux pumps were used as queries in BLASTP-based searches against the *Yp*KIM and *Yp*CO92 genomes. Potential RobA~Ec~binding sites were searched for using the navigator function in Artemis and the naked eye.

Abbreviations
=============

AMP: ampicillin; APR: apramycin; CHL: chloramphenicol; CIP: ciprofloxacin; CT: cycle threshold; DOX: doxycycline; *Ec*: *E. coli*; GEN: gentamicin; HIB: heart infusion broth; KAN: kanamycin; LB: Luria-Bertani; LVX: levofloxacin; MDR: multidrug-resistant; MFS: major facilitator superfamily; NAL: nalidixic acid; OFX: ofloxacin; RND: resistance-nodulation-cell division; STR: streptomycin; TBA: tryptose blood agar base; TET: tetracycline; *Yp*: *Y. pestis*.

Availability & requirements
===========================

CD-Search: <http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml>

Select Agent Program: <http://www.cdc.gov/od/sap/sap/exclusion.htm>

BLAST: <http://www.ncbi.nlm.nih.gov/blast/Blast.cgi>

Yersinia pestis KIM Genome Page: <http://cmr.tigr.org/tigr-scripts/CMR/GenomePage.cgi?org=ntyp02>

University of Wisconsin *E. Coli* Genome Project: <http://www.genome.wisc.edu/sequencing/pestis.htm>

Wellcome Trust, Sanger Institute, Yersinia pestis data: <http://www.sanger.ac.uk/Projects/Y_pestis/>

Artemis genome viewer software: <http://www.sanger.ac.uk/Software/Artemis/>
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